Aim. To study the clinical course of COVID-19 in patients with chronic obstructive pulmonary disease (COPD). Design. A retrospective, single-center, longitudinal study. Materials and methods. The study included 154 patients hospitalized for COVID-19, including 103 with COPD and 51 patients without COPD and a smoking history. The presence of COVID-19 was confirmed by laboratory tests (smear on the RNA of the SARS-CoV-2 virus from the upper respiratory tract by polymerase chain reaction) and/or clinically and radiologically. The diagnosis of patients with COPD was documented in accordance with the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. All patients underwent demographic assessment, measurement of body mass index, evaluation of disease symptoms, and objective and instrumental studies. Objective laboratory tests included general and biochemical blood tests, assessment of C-reactive protein levels upon admission and in dynamics, and coagulation studies. Instrumental studies included computed tomography of chest organs. Pulse oximetry was used to measure blood oxygen saturation and detect respiratory failure. These measurements were used to assess the severity of hypoxia. Results. Patients with COVID-19 and COVID-19 and COVID-19 without COPD were comparable by age, severity of lung injury and anti-IL6 therapy. In the majority of cases COPD in patients with COVID-19 has occurred with frequent exacerbations, had pronounced clinical manifestations and was presented by bronchitic and mixed phenotypes. The clinical features of COVID-19 in patients with COPD include statistically significantly lower levels of oxygen saturation (SpO2), total protein, alanine aminotransferase, aspartate aminotransferase, and respiratory rate, as well as higher oxygen flow rate, white blood cell count, absolute neutrophil and eosinophil counts, D-dimer concentrations, and creatinine. In addition, there is a significant increase in the need for non-invasive ventilation and mortality in patients with COVID-19 and COPD. The precursors of deaths in the COVID-19 and COPD group were older age, excessive body mass, emphysema > 4.8% and associated diabetes mellitus. Conclusion. Since COPD occurs later in life and is often associated with other conditions, the combination of COVID-19 and COPD may have several negative interactions that can lead to a poor outcome from COVID-19. Additionally, thrombosis and coagulopathy are common in severe cases of both COVID-19 and COPD. It is therefore important to understand if pre-existing endothelial dysfunction in COPD patients increases their risk of vascular complications during COVID-19. Furthermore, research has shown that COPD is also associated with worse outcomes from COVID-19, regardless of age and other related conditions. Keywords: COVID-19, chronic obstructive pulmonary disease, phenotypes, emphysema, outcomes